Global Clopidogrel Bisulfate Tablets Market Size, Share, and COVID-19 Impact Analysis, By Dose (75mg, 300mg, and Others), By Indications (Stroke, Cardiovascular Diseases, Peripheral Artery Disease, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Clopidogrel Bisulfate Tablets Market Insights Forecasts to 2033

• The Global Clopidogrel Bisulfate Tablets Market Size was estimated at USD 1.21 Billion in 2023
• The Market Size is expected to Grow at a CAGR of around 4.39% from 2023 to 2033
• The Worldwide Clopidogrel Bisulfate Tablets Market Size is expected to reach USD 1.86 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Clopidogrel Bisulfate Tablets Market Size is predicted to exceed USD 1.86 Billion by 2033, growing at a CAGR of 4.39% from 2023 to 2033.

Market Overview

The clopidogrel bisulfate tablet market involves the development, production, and commercialization of the clopidogrel bisulfate tablets used as a platelet aggregation inhibitor to treat myocardial infarction and strokes in patients with cardiovascular diseases or blood circulation disorders. Clopidogrel bisulfate is a platelet inhibitor used to reduce the risk of myocardial infarction and stroke in patients with non-ST elevated acute coronary syndrome, ST-elevated myocardial infarction, recent MI, stroke, or established peripheral arterial disease. The clopidogrel bisulfate is the salt form of the clopidogrel and it is more stable than clopidogrel. The marketed products of the clopidogrel bisulfate tablets are CLOPIX, Clopidac-75. The increasing prevalence of the cardiovascular diseases accelerates the need for medications such as clopidogrel and its products resulting the market growth. For instance, the data provided by the World Health Organization (WHO) states that cardiovascular diseases (CVDs) are the leading cause of death globally, with 17.9 million deaths in 2019, accounting for 32% of all global deaths. 85% of these deaths were due to heart attacks and strokes. Most cardiovascular deaths occur in middle-income countries. Out of 17 million premature deaths due to noncommunicable diseases, 38% were caused by CVDs. Preventing CVDs involves addressing risk factors like tobacco use, unhealthy diet, inactivity, alcohol use, and air pollution. Early detection is crucial for effective management.

Report Coverage

This research report categorizes the global clopidogrel bisulfate tablets market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global clopidogrel bisulfate tablets market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global clopidogrel bisulfate tablets market.

Driving Factors:

Rising prevalence of cardiovascular diseases:

The increasing prevalence of cardiovascular diseases (CVDs) has led to a surge in demand for antiplatelet medications like clopidogrel bisulfate. CVDs, which affect the heart or blood vessels, are caused by various risk factors such as high blood pressure, unhealthy diet, cholesterol, diabetes, air pollution, obesity, tobacco use, kidney disease, physical inactivity, harmful alcohol use, and stress. For instance, the data provided by the World Heart Federation states that over half a billion people worldwide are affected by CVDs, which accounted for 20.5 million deaths in 2021, a third of all global deaths and an increase from the estimated 121 million CVD deaths.

Increasing proportion of the geriatric population:

The growing age prone to cause cardiovascular diseases, attributable to alterations in the cardiovascular system like stiffening of the arteries and heightened oxidative stress. Since older people often suffer from multiple comorbidities, dealing with cardiovascular diseases in this demographic can be quite complicated. The increasing number of elderly individuals is fueling the demand for drugs such as clopidogrel bisulfate tablets, which is expected to rise consistently due to the growing incidence of cardiovascular diseases and an emphasis on preventive healthcare. Changes in the cardiovascular system associated with aging increase the risk of conditions such as hypertension, atherosclerosis, and heart failure in older adults. Therefore, the growing magnitude of the geriatric population escalates for the cardiac treatment, which increases the demand for the clopidogrel bisulfate tablets resulting in the expansion of the market.

Restraining Factors

The medication clopidogrel bisulfate, which is utilized for addressing bleeding complications, may face discontinuation among specific patient demographics due to of its adverse effects. The presence of generic versions can initiate pricing competitiveness, affecting the profitability of branded products. The emergence of newer antiplatelet medications could lead to a decrease in demand.

Market Segmentation

The global clopidogrel bisulfate tablets market share is classified into dose, indications, and distribution channel.

• The 75mg segment accounted for a significant share in 2023 and is anticipated to grow at a remarkable CAGR throughout the forecast period.

Based on the dose, the global clopidogrel bisulfate tablets market is categorized into 75mg, 300mg, and others. Among these, the 75mg segment accounted for a significant share in 2023 and is anticipated to grow at a remarkable CAGR throughout the forecast period. The segmental expansion is attributed to the extensive usage in the management of cardiovascular diseases, greater efficacy, compatibility with adult and geriatric populations, prevention from the formation of blood clots, and minimization of the complications associated with peripheral artery disease.

• The cardiovascular diseases segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global clopidogrel bisulfate tablets market is categorized into stroke, cardiovascular diseases, peripheral artery disease, and others. Among these, the cardiovascular diseases segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is owing to the increasing prevalence of cardiovascular diseases, the growing use of clopidogrel as an antiplatelet drug during the treatment of myocardial infarction, sedentary lifestyles, eating unhealthy foods, lack of physical activity, and growing proportion of the geriatric population.

• The hospital pharmacies segment held a significant share in 2023 and is expected to grow at a remarkable CAGR throughout the projected timeframe.

Based on the distribution channel, the global clopidogrel bisulfate tablets market is categorized into retail pharmacies, online pharmacies, hospital pharmacies, and others. Among these, the hospital pharmacies segment held a significant share in 2023 and is expected to grow at a remarkable CAGR throughout the projected timeframe. The segment expansion is facilitated by the availability of clopidogrel bisulfate tablets in bulk, cost effectiveness, compounding and dispensing of drug facilities, specialized services, and providing quality medications with dosage regimen.

Regional Segment Analysis of the Global Clopidogrel Bisulfate Tablets Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global clopidogrel bisulfate tablets market over the predicted timeframe.

North America is anticipated to hold the largest share of the global clopidogrel bisulfate tablets market over the predicted timeframe. This is owing to its established healthcare system, the high incidence of cardiovascular diseases, and substantial healthcare spending. The growth of the market is facilitated by major pharmaceutical companies and favorable reimbursement policies. The accessibility and affordability of clopidogrel have increased due to the availability of generic versions, leading to a rise in its adoption. In North America, the advanced healthcare systems and high healthcare expenditures facilitate the widespread use of Clopidogrel, while strict regulations guarantee its safety and effectiveness.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. Rapid economic development in the Asia Pacific region is leading to increased investments in healthcare and greater awareness of cardiovascular diseases, thus driving demand for advanced medical treatments. China and India are considered significant drivers of market growth due to their substantial populations and enhanced healthcare systems. This provides pharmaceutical companies the chance to broaden their presence and take advantage of the expanding patient population. Furthermore, the clopidogrel bisulfate market is growing as a result of increased awareness regarding preventive care and the use of generic formulations. The market's expansion is additionally aided by progress in drug delivery systems and pharmaceutical technologies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global clopidogrel bisulfate tablets market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Torrent Pharmaceuticals Ltd.
• Sandoz International GmbH
• Aurobindo Pharma Limited
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis AG
• Cipla Inc.
• Glenmark Pharmaceuticals Ltd.
• Lupin Limited
• Apotex Inc.
• Dr. Reddy Laboratories Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2023, Ascendia Pharmaceuticals developed a novel nanoemulsion IV formulation for clopidogrel using EmulSol® nanotechnology, which has received Investigational New Drug (IND) approval from the FDA. The collaboration between Ascendia and AcuteBio aims to improve treatment methods for coronary artery disease (CAD), particularly for stent placements.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global clopidogrel bisulfate tablets market based on the below-mentioned segments:

Global Clopidogrel Bisulfate Tablets Market, By Dose

• 75mg
• 300mg
• Others

Global Clopidogrel Bisulfate Tablets Market, By Indications

• Stroke
• Cardiovascular Diseases
• Peripheral Artery Disease
• Others

Global Clopidogrel Bisulfate Tablets Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies
• Others

Global Clopidogrel Bisulfate Tablets Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa